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Editorial on the Research Topic
Evolving Picture of Calcium Handling in Cardiac Disease
Cardiovascular diseases (CVDs) underlie a high rate of mortality worldwide. Both acquired and
inherited CVDs are closely related to ionic channelopathies, compromising the expression and
function of a wide number of ion channels. Ca2+ mishandling has been associated with several
CVDs, such as those involved in metabolic disorders, hypertrophy, heart failure, and several
inherited heart diseases that implicate cardiac dysfunction and arrhythmias (Kushnir et al., 2018).
Moreover, the archives of biomedical and life sciences are showing a multitude of contributions
related to this topic, demonstrating the high interest of the scientific community in this specific
research field. Indeed, Ca2+ is the key regulator of the Ca2+ induced Ca2+ release (CICR) process,
the main actor in cardiac excitation-contraction coupling (ECC) (Fabiato, 1983). Briefly, ECC
begins with membrane depolarization of cardiomyocytes, activating sarcolemmal L-type voltage-
dependent Ca2+ channels, thus promoting an inward Ca2+ current (ICaL) that activates the
intracellular Ca2+ channel/ryanodine receptor type 2 (RyR2), located at the sarcoplasmic reticulum
(SR), triggering a transient increase of cytosolic Ca2+ levels, and eliciting cell contraction. To get
new insights into these processes, Aguilar-Sanchez et al. evaluated in an elegant study whether the
autonomous system regulates ECC in endocardial and epicardial layers from intact beating mouse
hearts. The authors recorded action potentials (APs), Ca2+ transients, and Ca2+ currents in whole
hearts, demonstrating that the Ca2+ influx occurring in AP phase 1, and not in phase 2, triggers
ECC (Aguilar-Sanchez et al.).
After contraction, relaxation takes place when cytosolic Ca2+ levels return to physiological
resting levels by twomainmechanisms, the Sarco/Endoplasmic ReticulumCa2+ ATPase (SERCA2a
pump) and the sarcolemma Na+- Ca2+ exchanger (NCX) (Bers, 2002). More recently, other
elements have been described as involved in the control of cardiac intracellular Ca2+ handling, such
as transient receptor potential (TRP) channels or organelles such as the nucleus or mitochondria
that also rely on transporters or channels for Ca2+ dynamics. The fine orchestration of all these
elements results in adequate ECC and cell contraction.
Since its discovery (Inui et al., 1987), RyR2 has acquired special interest, and a large number
of studies have analyzed whether changes in the structure, genetics, and function of this macro
channel are involved in the pathogenesis of several CVDs. Post-translational modifications of
RyR2, such as phosphorylation and oxidation, have gained major attention and have been related
to channel dysfunction in some CVDs such as heart failure. Leading groups in the field have
focused their interest in analyzing the physio-pathological regulation of RyR2 function by protein
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kinase A or calmodulin kinase type II-dependent
phosphorylation. In this line, Federico et al. have performed
an interesting review article that addresses the most relevant
findings related to changes in SR-Ca2+ uptake and post-
translational modifications in RyR2, such as the phosphorylation
and oxidation both linked to arrhythmias and other cardiac
disturbances. In the same line, Fernández-Miranda et al.
demonstrated in a prediabetic rat model of metabolic syndrome
an “in situ” impairment of RyR2 function elicited by reduced
levels of RyR2 phosphorylation, together with depressed SR-
Ca2+ uptake by SERCA2a, which are responsible for the poor
cardiac outcome linked to this metabolic disorder.
In addition to phosphorylation, redox modifications
of RyR2 such as S-nitrosylation and S-glutathionylation
have emerged as new and potent modulators of channel
function, demonstrating a crosslink between oxidation and
phosphorylation changes. In many cases, changes in the redox
state of RyR2 participate in the generation of abnormal Ca2+
diastolic release, supporting an additional pro-arrhythmogenic
mechanism in several CVDs. Nikolaienko et al. recapitulate in
a remarkable review article the most significant findings related
to whether redox modifications of RyR2 can induce channel
dysfunction. In this line, Hamilton et al. tested the efficacy
of mitochondria-targeted pharmacological interventions to
attenuate cardiac arrhythmia at the cellular level and in “ex-
vivo” hypertrophied thoracic aortic-banded mouse hearts. The
authors demonstrated that the abnormal mitochondrial Ca2+
accumulation induced an excessive production of reactive oxygen
species that promoted the oxidation of RyR2 and enhanced its
activity, inducing a pro-arrhythmic spontaneous Ca2+ release
(Hamilton et al.).
Besides this, increased reactive oxygen species can also activate
the inflammatory response. In many cases, pro-inflammatory
mediators result in intracellular Ca2+ mishandling. In this
regard, Val-Blasco et al. have determined whether the lack of
the pro-inflammatorymediator NOD1 (a specific innate immune
receptor) improves the β-adrenergic regulation of intracellular
Ca2+ dynamics in failing hearts. NOD1 is a well-known
activator of the inflammatory response. An increasing amount
of evidences suggest that inflammatory mediators participate in
the progression of CVDs (Adamo et al., 2020). Inflammation
and metabolic disorders are closely related, and in many cases
involve changes in cardiac Ca2+ homeostasis. A well-designed
report, published by Delgado et al. has addressed the role
of the inflammatory mediator tumor necrosis factor (TNF)-α
in the modulation of intracellular Ca2+ handling in a mouse
model of diabetes type II (db/db). The authors demonstrated
a different regulation of Ca2+ handling mediated by TNF-α in
male compared to female db/db mice, supporting the idea of a
cardioprotective role of gender in the Ca2+ mishandling linked
to a pro-inflammatory environment (Delgado et al.).
Another interesting contribution has been supported by
Cagalinec et al. using a transgenic rat model with a mutation
in the gene encoding the wolframin protein (Wfs1−e5/−e5),
linked to diabetic and neurological complications. These authors
demonstrated that Wfs1−e5/−e5 rats are euglycemic at 4 months
old and ventricular cardiomyocytes isolated from Wfs1−e5/−e5
animals showed a higher duration of Ca2+ release; conjecturing
a prolongation of RyR2 channel openings and modification
in the RyR2 gating mediated by Wfs1 in cardiac cells
(Cagalinec et al.).
All these functional studies and reviews have contributed
to a better understanding of the basis of CVDs arising from
ion channel dysfunction and intracellular Ca2+ mishandling.
These advances have also helped in the design of new
drugs targeting ion channels, looking for more effective CVD
treatments. Monsalvo-Villegas et al. performed an interesting
pharmacological study describing a protective role of pirfenidone
administration in isolated cardiomyocytes through modulation
of CICR, ECC, and cell contractility. This study provides
new explanations regarding the cardioprotective actions of
pirfenidone (Monsalvo-Villegas et al.).
As previously mentioned, TRP channels have emerged as
key partners in the pathogenesis of several CVDs, such as
hypertrophy. Falcón et al. compiled in a commendable and well-
organized review article the involvement of various subtypes of
TRPs in cardiac physiology and CVDs. The authors particularly
described the involvement of these receptors in heart remodeling
linked to cardiac hypertrophy, uncovering a new and interesting
field of research (Falcón et al.).
In addition to cardiac function, Ca2+ regulates vascular
function. In this setting, Gutiérrez et al. have demonstrated
in a well-conducted study whether different signaling
pathways (PI3K, MAPK, and PKC) modulate Ca2+
entry and intracellular Ca2+ mobilization coupled to α1-
adrenoceptor activation in the vascular smooth muscle of rat
resistance arteries.
To conclude, the compendium of articles included in this
Research Topic presents a new and interesting scenario for
near future research related to novel actors in the picture of
intracellular Ca2+ mishandling associated with CVDs.
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